Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084344 | 0.90 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084345 | 0.88 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17056217 | 0.88 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL18218064 | 0.88 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084342 | 0.87 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084338 | 0.86 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084336 | 0.84 | POLB (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084307 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17084347 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL18812939 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9684238-B2 | Fluorene-type compound, photopolymerization initiator comprising said fluorene-type compound, and photosensitive composition containing said photopolymerization initiator | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9684238-B2 | Fluorene-type compound, photopolymerization initiator comprising said fluorene-type compound, and photosensitive composition containing said photopolymerization initiator | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150259321-A1 | FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR | DAITO CHEMIX CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150259321-A1 | FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR | DAITO CHEMIX CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259321-A1 | FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR | AFF1, AFF2, FTO | NPC1 3715/4885RAB9A 2860/4885SMN1; SMN2 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.